Kite's CAR T therapy clears cancer in 71% of ALL patients


Gilead Sciences' subsidiary Kite Pharma has released new data from its midstage trial that assessed its chimeric antigen receptor T-cell therapy Tecartus in adult patients with acute lymphoblastic leukemia that found the anti-CD19 cell therapy was capable of wiping out cancer in 71% of 55 participants who had been previously treated. Data also showed Tecartus generated a response that lasted for a median of 12.8 months, based on findings presented at the annual meeting of the American Society of Clinical Oncology.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.